Vanguard Group Inc Bio Path Holdings Inc Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.36 - $0.75 $42,449 - $88,435	117,914 Added 77.52%	270,029 $124,000
Q3 2023 Nov 14, 2023	SELL	$0.36 - $1.78 $31,309 - $154,808	-86,971 Reduced 36.38%	152,115 $56,000
Q1 2023 May 15, 2023	BUY	$1.39 - $2.26 $24,217 - $39,375	17,423 Added 7.86%	239,086 $332,000
Q4 2022 Feb 10, 2023	BUY	$1.32 - $2.81 $199 - $424	151 Added 0.07%	221,663 $334,000
Q2 2022 Aug 12, 2022	BUY	$2.83 - $4.02 $15,423 - $21,908	5,450 Added 2.52%	221,512 $857,000

Q4 2021 Feb 14, 2022	SELL	$3.77 - $5.24 $11,046 - $15,353	-2,930 Reduced 1.34%	216,062 $815,000
Q2 2021 Aug 13, 2021	BUY	$5.13 - $7.63 $1.12 Million - $1.67 Million	218,992 New	218,992 $1.46 Million

Ticker BPTH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,160,160
Market Cap $13M
Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.